Subgroup	No.	Triflusal No. of events (%/yr)	Clopidogrel No. of events (%/yr)	Hazard ratio (95% CI)	*P* for interaction
Age					0.373
<65 years	285	8 (2.3)	9 (2.4)	0.93 (0.36–2.41)	
≥65 years	199	8 (3.8)	5 (1.9)	1.83 (0.60–5.59)	
Sex					0.284
Male	323	9 (2.3)	10 (2.4)	0.91 (0.37–2.25)	
Female	161	7 (4.2)	4 (1.8)	2.12 (0.65–7.25)	
Time from index event to randomization					0.399
≤7 days	270	10 (3.6)	8 (2.1)	1.64 (0.65–4.16)	
≥7 days	214	6 (2.1)	6 (2.4)	0.86 (0.28–2.65)	
TOAST classification qualifying stroke					0.171
LAA	100	8 (9.2)	3 (2.5)	3.23 (0.85–12.19)	
Lacune	264	4 (1.3)	7 (1.9)	0.68 (0.20–2.32)	
SUD	120	4 (2.4)	4 (2.7)	0.83 (0.21–3.21)	
Diabetes mellitus					0.257
Yes	146	3 (1.8)	5 (2.8)	0.62 (0.15–2.60)	
No	338	13 (3.3)	9 (2.0)	1.58 (0.68–3.70)	
Hypertension					0.070
Yes	296	12 (3.5)	6 (1.5)	2.21 (0.83–5.89)	
No	188	4 (1.9)	8 (3.5)	0.52 (0.16–1.74)	
Current tobacco smoker					0.810
Yes	193	6 (2.8)	6 (2.3)	1.09 (0.35–3.37)	
No	291	10 (2.9)	8 (2.1)	1.34 (0.53–3.39)	



Supplementary Figure 1. Hazard ratios for the primary outcome in subgroups of participants with a poor genotype for clopidogrel metabolism. CI, confidence interval; LAA, large artery atherosclerosis; SUD, stroke of undetermined aetiology.